Literature DB >> 30903371

T-cell aging in end-stage renal disease: an evolving story with CMV.

TienYu Owen Yang1,2, Yi-Fang Chuang3,4, Yen-Ling Chiu5,6,7.   

Abstract

Established evidence from the last decade has suggested that chronic cytomegalovirus infection has strong impact on the human immune system, resulting in aggravated aging-associated T-cell changes that are associated with poorer vaccination responses, cardiovascular disease and shortened survival. Patients with end-stage renal disease (ESRD), the most severe form of chronic kidney disease, exhibit premature aging phenotypes in almost all organ systems, including the immune system. Longitudinal studies of T-cell aging in healthy humans have been scanty because it requires a large number of study subjects and a study duration for decades. In recent years, it became clear that ESRD patients with cytomegalovirus (CMV) infection exhibit enhanced aging-related immune changes than CMV-seropositive individuals without renal disease, including chronic inflammation, decreased numbers of naïve CD4+ and CD8+ T cells, increased clonality of memory T cells with skewed repertoire and shortened telomeres. These findings lead to the hypothesis that the uremic milieu and treatment for renal failure can lead to premature aging of T cells independent from CMV infection and suggest that ESRD can be an important disease model for studying human aging. Future studies deciphering the underlying mechanisms of accelerated T cell aging in ESRD patients may eventually reveal additional insights into T-cell persistence and function during aging in CMV-seropositive, non-ESRD individuals.

Entities:  

Keywords:  Aging; Cytomegalovirus; End-stage renal disease; T cell

Mesh:

Year:  2019        PMID: 30903371     DOI: 10.1007/s00430-019-00596-8

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  51 in total

1.  Dysfunctional CMV-specific CD8(+) T cells accumulate in the elderly.

Authors:  Qin Ouyang; Wolfgang M Wagner; Wei Zheng; Anders Wikby; Ed J Remarque; Graham Pawelec
Journal:  Exp Gerontol       Date:  2004-04       Impact factor: 4.032

2.  Dendritic cell inhibition is connected to exhaustion of CD8+ T cell polyfunctionality during chronic hepatitis C virus infection.

Authors:  Ian Gaël Rodrigue-Gervais; Hawley Rigsby; Loubna Jouan; Dominike Sauvé; Rafick-Pierre Sékaly; Bernard Willems; Daniel Lamarre
Journal:  J Immunol       Date:  2010-02-19       Impact factor: 5.422

3.  Healthy aging and latent infection with CMV lead to distinct changes in CD8+ and CD4+ T-cell subsets in the elderly.

Authors:  Birgit Weinberger; Lutfan Lazuardi; Ilka Weiskirchner; Michael Keller; Christoph Neuner; Karl-Heinz Fischer; Ber Neuman; Reinhard Würzner; Beatrix Grubeck-Loebenstein
Journal:  Hum Immunol       Date:  2006-12-05       Impact factor: 2.850

4.  Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging.

Authors:  F F Fagnoni; R Vescovini; G Passeri; G Bologna; M Pedrazzoni; G Lavagetto; A Casti; C Franceschi; M Passeri; P Sansoni
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

5.  Cytomegalovirus-induced effector T cells cause endothelial cell damage.

Authors:  Pablo J E J van de Berg; Si-La Yong; Ester B M Remmerswaal; René A W van Lier; Ineke J M ten Berge
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

6.  Latency for cytomegalovirus impacts T cell ageing significantly in elderly end-stage renal disease patients.

Authors:  L Huang; A W Langerak; C C Baan; N H R Litjens; M G H Betjes
Journal:  Clin Exp Immunol       Date:  2016-08-19       Impact factor: 4.330

7.  Differential effects of age, cytomegalovirus-seropositivity and end-stage renal disease (ESRD) on circulating T lymphocyte subsets.

Authors:  Nicolle Hr Litjens; Elly A de Wit; Michiel Gh Betjes
Journal:  Immun Ageing       Date:  2011-01-08       Impact factor: 6.400

8.  Decreased naive and increased memory CD4(+) T cells are associated with subclinical atherosclerosis: the multi-ethnic study of atherosclerosis.

Authors:  Nels C Olson; Margaret F Doyle; Nancy Swords Jenny; Sally A Huber; Bruce M Psaty; Richard A Kronmal; Russell P Tracy
Journal:  PLoS One       Date:  2013-08-23       Impact factor: 3.240

9.  Age-related differences in polyfunctional T cell responses.

Authors:  Puja Van Epps; Richard Banks; Htin Aung; Michael R Betts; David H Canaday
Journal:  Immun Ageing       Date:  2014-10-23       Impact factor: 6.400

10.  Functional Diversity of Cytomegalovirus-Specific T Cells Is Maintained in Older People and Significantly Associated With Protein Specificity and Response Size.

Authors:  Martha Bajwa; Serena Vita; Rosanna Vescovini; Martin Larsen; Paolo Sansoni; Nadia Terrazzini; Stefano Caserta; David Thomas; Kevin A Davies; Helen Smith; Florian Kern
Journal:  J Infect Dis       Date:  2016-08-11       Impact factor: 5.226

View more
  4 in total

1.  Emergence of T cell immunosenescence in diabetic chronic kidney disease.

Authors:  Ju-Ying Jiang; Yu-Sen Peng; Yi-Fang Chuang; Yen-Ling Chiu; Wan-Chuan Tsai; Ruo-Wei Hung; I-Yu Chen; Kai-Hsiang Shu; Szu-Yu Pan; Feng-Jung Yang; Te-Tien Ting
Journal:  Immun Ageing       Date:  2020-10-20       Impact factor: 6.400

2.  Human cytomegalovirus seroprevalence and titres in solid organ transplant recipients and transplant donors in Seoul, South Korea.

Authors:  Yeonju La; Da Eun Kwon; Seul Gi Yoo; Kyoung Hwa Lee; Sang Hoon Han; Yong Goo Song
Journal:  BMC Infect Dis       Date:  2019-11-08       Impact factor: 3.090

3.  Decreased Peripheral Naïve T Cell Number and Its Role in Predicting Cardiovascular and Infection Events in Hemodialysis Patients.

Authors:  Fangfang Xiang; Xuesen Cao; Xiaohong Chen; Zhen Zhang; Xiaoqiang Ding; Jianzhou Zou; Bo Shen
Journal:  Front Immunol       Date:  2021-03-17       Impact factor: 7.561

Review 4.  Immunosenescence: A Critical Factor Associated With Organ Injury After Sepsis.

Authors:  Xuan Lu; Yun-Mei Yang; Yuan-Qiang Lu
Journal:  Front Immunol       Date:  2022-07-18       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.